SCHEMBL74367

SCHEMBL74367

O=C(CS)Oc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.52
ELANE P08246 1/20 0.47
TDP1 Q9NUW8 2/20 0.45
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALOX15 P16050 2/20 0.45
PRSS1 P07477 1/20 0.45
PRSS2 P07478 1/20 0.45
PRSS3 P35030 1/20 0.45
HSD17B10 Q99714 2/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 3/20 0.44
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 3/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 1/20 0.41
NSD2 O96028 1/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27909970 0.98 CYP19A1 (0.50) CYP19A1ELANETDP1ATML3MBTL1
SCHEMBL9569687 0.84 KMT2A (0.59) KMT2ALMNAMEN1
SCHEMBL231450 0.84 CYP19A1 (0.53) CYP19A1ELANETDP1ATML3MBTL1
SCHEMBL2551013 0.83 PRSS1 (0.50) CYP19A1ELANETDP1ATML3MBTL1
SCHEMBL23818361 0.82 KMT2A (0.47) ELANEHSD17B10MAPTALDH1A1KMT2A
SCHEMBL43742 0.81 KMT2A (0.61) CYP19A1ELANETDP1ATML3MBTL1
SCHEMBL153387 0.81 CYP19A1 (0.55) CYP19A1ELANETDP1ATML3MBTL1
SCHEMBL25527343 0.81 HSD17B10 (0.52) ELANEHSD17B10KMT2AHTT
SCHEMBL10575704 0.81 PRSS1 (0.49) CYP19A1ELANETDP1ATML3MBTL1
SCHEMBL7631432 0.79 PRSS1 (0.55) CYP19A1TDP1PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1747 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115155-A1 STABLE FORMS OF CAPSAICIN PALMITATE FOR THE TREATMENT OF PAIN CHORDA PHARMA INC (US) 2026-04-30 US claimed
US-20250228759-A1 ANTI-AGING COSMETIC COMPOSITIONS COMPRISING XANTHOMMATIN SEASPIRE INC (US) 2025-07-17 US claimed
WO-2023078310-A1 NUTRIENT SOLUTION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 长春圣博玛生物材料有限公司 2023-05-11 WO claimed
CN-116077358-A Nutrient solution and preparation method and application thereof 长春圣博玛生物材料有限公司 2023-05-09 CN claimed
WO-2023009502-A1 ANTI-AGING COSMETIC COMPOSITIONS COMPRISING XANTHOMMATIN SEASPIRE, INC. (US) 2023-02-02 WO claimed
US-10219994-B2 Method for the simultaneous permanent shaping and dyeing of keratinic fibers HENKEL AG & CO. KGAA (DE) 2019-03-05 US claimed
US-9943477-B2 Emulsion compositions containing a novel preservative system L'OREAL (FR) 2018-04-17 US claimed
US-20180015060-A1 HEALING TOPICAL COMPOSITION FLORENGALE, LLC 2018-01-18 US claimed
EP-3250196-A1 HEALING TOPICAL COMPOSITION Florengale, LLC (US) 2017-12-06 EP claimed
EP-2361079-B1 METHOD FOR DYEING AND SHAPING KERATIN FIBERS HENKEL AG & CO KGAA (DE) 2017-05-31 EP claimed
US-20050238681-A1 Storage-stable compositions of glycerol monoalkyl ethers SCHULKE & MAYR GMBH (DE) 2005-10-27 US claimed
US-20030149097-A1 Storage-stable compositions of glycerol monoalkyl ethers ASHLAND SPECIALTIES DEUTSCHLAND GMBH (DE) 2003-08-07 US claimed
EP-1301168-A1 STORAGE-STABLE COMPOSITIONS OF GLYCEROL MONOALKYL ETHERS Air Liquide Santé (International) (FR) 2003-04-16 EP claimed
WO-2001093825-A1 STORAGE-STABLE COMPOSITIONS OF GLYCEROL MONOALKYL ETHERS AIR LIQUIDE SANTE (INTERNATIONAL) (FR) 2001-12-13 WO claimed
JP-2000512663-A 2000-09-26 JP claimed
EP-1003469-A2 FRAGRANCE PRECURSORS GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) 2000-05-31 EP claimed
US-5925366-A PERMEATION/BINDING AGENT, THIO CROSSLINKING AGENT, AND CHELATE COMPOUND REVLON CONSUMER PRODUCTS CORPORATION (US) 1999-07-20 US claimed
US-5785959-A MIXTURE CONTAINING A PERMEATION/BINDING AGENT, A THIO CROSSLINKING AGENT, A CHELATING AGENT, WATER AND AN OIL REVLON CONSUMER PRODUCTS CORPORATION (US) 1998-07-28 US claimed
WO-1998006376-A1 NAIL STRENGTHENING COMPOSITIONS AND A METHOD FOR STRENGTHENING NAILS REVLON CONSUMER PRODUCTS CORPORATION (US) 1998-02-19 WO claimed
WO-1997030687-A2 FRAGRANCE PRECURSORS GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) 1997-08-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180015060-A1 HEALING TOPICAL COMPOSITION CUTA, CSDE1, SRI CYP19A1 2488/4885ELANE 1760/4885TDP1 1330/4885
US-20260115155-A1 STABLE FORMS OF CAPSAICIN PALMITATE FOR THE TREATMENT OF PAIN TRPV1, SPTLC3, FFAR3 CYP19A1 2204/4885ELANE 4050/4885TDP1 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.